Purified EPA fish oil reduces cardiovascular risk

Commercial-stage biotech Amarin Corporation (NASDAQ:AMRN said that an independent study supported the benefit of purified eicosapentaenoic acid (EPA), a component in its heart disease therapy Vascepa/Vazkepa.

RESPECT-EPA trial funded by the Japanese Heart Foundation marginally achieved statistical significance with a 21.5% reduction in the primary composite endpoint related to cardiovascular risk. It also indicated statistical significance for a 26.6% reduction in the secondary composite endpoint.

Amarin (AMRN) said that the RESPECT-EPA was the third study to highlight the beneficial impact of purified EPA in lowering cardiovascular outcomes in patients with coronary artery disease.

The results were part of a presentation at the American Heart Association (AHA) 2022. Other presentations included in vitro data supporting the antioxidant effect of EPA on low-density lipoprotein (LDL) compared to mineral oil.

Vascepa is a fish oil-derived therapy approved in the U.S. for high-risk patients who continue to suffer from cardiovascular risk after statin therapy.


Evidence does seem to be converging that EPA-only fish oil is best, although there’s definitely still debate. You can buy OTC version of Vascepa (Carlson Elite EPA, which is EPA ethyl ester 1 gram per cap). It’s pricey, but you get 120 caps in a bottle for about $60. I take 1 per day and also give 1 per day to my dog who has inflammatory bowel disease.

1 Like

It’s interesting. I eat some salmon almost daily, but do not take fish oil. I got a complete free fatty acid profile done and my DHA was upper normal, but my EPA was off the charts high. It can be done with food only it would seem.


Yes, I believe that Omega-3s are essential. Especially EPA. Whether you get it from food, supplements or both, omegas are one of the best ways to avoid deadly cardiovascular issues.